Development of Left Ventricular Diastolic Dysfunction With Preservation of Ejection Fraction During Progression of Infant Right Ventricular Hypertrophy

Kazuo Kitahori, MD, PhD; Huamei He, MD, PhD; Mitsuhiro Kawata, MD, PhD; Douglas B. Cowan, PhD; Ingeborg Friehs, MD; Pedro J. del Nido, MD; Francis X. McGowan, Jr, MD

Background—Progressive left ventricular (LV) dysfunction can be a major late complication in patients with chronic right ventricular pressure overload (eg, tetralogy of Fallot). Therefore, we examined LV function (serial echocardiography and ex vivo Langendorff) and histology in a model of infant pressure-load right ventricular hypertrophy (RVH).

Methods and Results—Ten-day-old rabbits (n=6 per time point, total n=48) that underwent pulmonary artery banding were euthanized at 2 to 8 weeks after pulmonary artery banding, and comparisons were made with age-matched sham controls. LV performance (myocardial performance index) decreased during the progression of RVH, although the LV ejection fraction was maintained. In addition, RVH caused significant septal displacement, reduced septal contractility, and decreased LV end-systolic and end-diastolic dimensions, resulting in LV diastolic dysfunction with the appearance of preserved ejection fraction. Significant septal and LV free-wall apoptosis (myocyte-specific TUNEL and activated caspase-3), fibrosis (Masson trichrome stain), and reduced capillary density (CD31 immunostaining) occurred in the pulmonary artery banding group after 6 to 8 weeks (all P<0.05).

Conclusion—This is the first study showing that pressure overload of the right ventricular resulting in RVH causes LV diastolic dysfunction while preserving ejection fraction through mechanical and molecular effects on the septum and LV myocardium. In particular, the development of RVH is associated with septal and LV apoptosis and reduced LV capillary density. (Circ Heart Fail. 2009;2:599-607.)

Key Words: right ventricular hypertrophy ■ heart failure with preserved ejection fraction ■ diastolic dysfunction ■ apoptosis ■ hypertrophy ■ right ventricle

Despite intensive basic science and clinical investigations, heart failure remains a leading cause of hospitalization and mortality worldwide.1-4 In patients with congenital heart disease (CHD), left ventricular (LV) dysfunction is an important cause of heart failure as well as an important prognostic factor.5-6 Furthermore, progressive LV dysfunction can be a major problem in patients with chronic right ventricular (RV) pressure load, such as tetralogy of Fallot, as they age.6,7 Several late complications, including sudden death, have been recognized after 2-stage tetralogy of Fallot repair and may be related not only to surgical factors (eg, ischemia-reperfusion injury and myocardial scarring) but also to time-dependent events (eg, pressure and/or volume overload and cyanosis) existing before and after repair that permanently damage the myocardium.8 Several investigators have suggested that these pathological changes lead to permanent heart damage and have found a lower incidence of ventricular arrhythmias among children who have undergone repair at younger ages. It is therefore generally agreed that long periods of pressure load should be avoided. However, underlying mechanistic factors have not been identified.

Clinical Perspective on p 607

The concept of heart failure with preserved ejection fraction (HFpEF) has been recently discussed in some detail9-14 and it seems that the phenomenon is related to diastolic LV dysfunction. In HFpEF, EF is maintained within normal limits despite the development of the signs and symptoms of heart failure. Some children with CHD suffer from HF despite preservation of EF, but HFpEF in CHD has not been investigated. Relevant to the aforementioned difficulties in long-term outcome in patients with lesions such as tetralogy of Fallot, there is compelling evidence that optimal RV systolic function requires a substantial contribution from the LV, most likely through the interventricular septum (IVS).15

One potential cellular mechanism of progressive myocardial dysfunction is apoptosis, which is a tightly regulated and enzymatically driven process in which cells die in response to
internal and/or external stimuli. It has hitherto been thought that terminally differentiated cells such as cardiomyocytes and neuronal cells have limited or no potential for regeneration by mitosis and are correspondingly less likely to undergo apoptosis. More recently, activation of cardiomyocyte apoptotic pathways has been recognized to contribute to decreases in cardiomyocyte number and potentially to altered cardiac function in several situations, such as postnatal maturation, hypertension, diabetes, aging, pressure overload, and ischemia-reperfusion injury. Insufficient capillary angiogenesis may be an important contributing factor in hypertrophic situations because the increased myocardial mass requires greater blood supply to maintain contractile processes, especially in the face of increased afterload. Alterated structural responses by the microvessels to the increased pressure load in the RV is a possible mechanism for chamber-specific dysfunction. However, it is unknown whether capillary density is altered in the LV as a result of RV hypertrophy (RVH).

**Methods**

**Experimental Model**

Ten-day-old New Zealand white rabbits weighing 160±33 g were used. All animals were cared for in accordance with the Principles of Laboratory Animal Care formulated by the National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences and published by the National Institutes of Health (publication No. 86-23, revised 1996). The protocols used in this study were approved by the Institutional Animal Care and Use Committee at Children’s Hospital, Boston.

The rabbits were anesthetized with intravenous injections of ketamine (50 mg/kg) and xylazine (2 mg/kg). After bupivacaine (0.1 to 0.2 mL) was injected subcutaneously, a left thoracotomy was performed through the second or third intercostal space. The pericardium was incised, and the main pulmonary artery was exposed. The pulmonary artery was banded with 2-0 silk, constricting it by 10% to 25% of its diameter. A 20-gauge catheter was placed in the left chest cavity, and the wound was closed. After as much air as possible had been evacuated through the catheter, it was removed. Sham-operated controls underwent an identical procedure, except for pulmonary artery banding (PAB). Buprenorphine (0.01 to 0.05 mg/kg) was administered for pain every 8 to 12 hours or as needed. All animals were observed for up to 2, 4, 6, and 8 weeks after the operation.

**Experimental Groups**

A total of 48 rabbits were assigned, 24 to the control group and the 24 to the PAB group. In each group, 6 rabbits were euthanized at 2, 4, 6, and 8 weeks after the operation. Immediately after the rabbits were deeply anesthetized with ketamine (100 mg/kg) and xylazine (5 mg/kg), their hearts were harvested. Once removed, they were attached to a perfusion apparatus (Langendorff system) through the aortic arch. For blood washout, a Krebs-Ringer solution (100 mmol/L NaCl, 4.7 mmol/L KCl, 1.1 mmol/L KH2PO4, 1.2 mmol/L MgSO4, 25 mmol/L NaHCO3, 1.7 mmol/L CaCl2, 11.5 mmol/L glucose D(+), pH 7.4) with insulin (10 U/L) was infused for several minutes, after which hearts were divided and blotted dry for wet weight measurement and subsequent analyses. The perfusion was performed at 37°C while O2 95% and CO2 5% were bubbled through the medium.

**Langendorff Perfusion**

A separate group (N=6 each) of hearts from sham and banded animals at 8 weeks were perfused with a Krebs-Ringer solution (see above) at 120 cm H2O for 30 minutes. Next, a balloon-tipped Millar micromanometry pressure catheter was inserted into the LV through the mitral valve for LV pressure-volume measurement. Balloon volume was adjusted by increments of 0.1 mL using a calibrated syringe, and both LV developed pressure and diastolic pressure were recorded; T (the half-time of LV pressure decline) was derived from these pressure-volume recordings using PVAN (AD Instruments) software.

---

**Figure 1.** Fresh-cut sections at midventricle level of whole rabbit hearts. A, The upper row images show representative control sections, and the lower row shows those from PAB hearts. RV thickness and chamber size increased in PAB hearts. There were significant differences in both absolute (B) and LV-normalized (C) RV mass within 4 weeks of PAB. †P<0.01 versus the control group.

---

by guest on July 6, 2017 http://circheartfailure.ahajournals.org/Downloaded from
Transthoracic echocardiography was performed every week after surgery until the rabbits were euthanized. The rabbits were anesthetized with intravenous injections of ketamine (50 mg/kg) and xylazine (2 mg/kg). Measurements of wall thickness at end-systole and end-diastole were made in M mode, and the LV dimensions at end-systole and end-diastole were also measured. To estimate tricuspid regurgitation and the pressure gradient at the PAB site, the peak pressure difference was estimated using spectral continuous-wave Doppler mode. EF and myocardial performance index (MPI) were determined. To calculate MPI, 2 periods were measured using the pulsed Doppler mode: the ejection time (c) and the time interval (d) between the end of LV inflow and onset. MPI was then calculated using the following formula:

$$\text{MPI} = \left[ \frac{d-c}{c} \right] \times 100,$$

and MPI was determined 3 times for each animal and recorded as the average of the 3 measurements. All studies were recorded on video home system videotape with simultaneous ECG.

**Apoptosis**

**TUNEL Staining**

Hearts were fixed in 4% paraformaldehyde, paraffin-embedded, and sectioned. TUNEL staining was performed in deparaffinized and rehydrated sections using the FragEL DNA fragmentation detection kit (EMD Biosciences, Inc, San Diego, Calif). The sections were incubated with terminal deoxynucleotidyl transferase and fluorescein-labeled dUTP. Then, mouse desmin monoclonal antibody (Sigma-Aldrich, St Louis, Mo) was used for identification of cardiomyocytes, followed by incubation with a secondary anti-mouse immunoreagent conjugated to the red-fluorescent Alexa-594TM fluorophore at a concentration of 1:200 (Molecular Probes, Eugene, Ore). All nuclei were stained with blue-fluorescent DAPI nucleic acid stain (Molecular Probes). Slides were visualized using a microscope with a Nikon 20× objective and a 10× eyepiece. Both the total number of nuclei and the number of TUNEL-positive nuclei in the LV and the IVS were counted in 10 random fields of vision per tissue section using Metamorph software (Universal Imaging Corporation, West Chester, Pa), and the results were expressed as the number of TUNEL-

---

Figure 2. Echocardiographic estimation of RV pressure. The peak pressure difference across the PAB site (A) and the tricuspid valve (B) was estimated from the peak flow velocity (spectral continuous-wave Doppler). By both measures, RV pressure progressively increased, stabilizing at approximately 7 weeks postoperatively.

Figure 3. Echocardiographic assessments of LV and septal dimensions and function. Thickness of the LV (A) and the septum (B): no significant difference was found in LV wall thickness, but the septum in the PAB group was significantly thinner than that of the controls. LV chamber dimensions (C) were significantly less in the PAB group than in the control group. In the key, (s) refers to end-systole and (d) to end-diastole. The MPI, shown in D, increased consistent with progression of LV dysfunction. EF is shown in E, but was likely to be "artificially" affected by the deformity of the LV as shown in C (see text also). *P<0.05 and †P<0.01 versus the control group.
positive cardiomyocyte nuclei (ie, simultaneously DAPI/TUNEL/desmin positive) per 1000 total cardiomyocyte nuclei.

**Western Immunoblotting**

After the hearts were harvested and flushed free of blood, specimens of LV and IVS were frozen in liquid nitrogen and stored at −80°C. These tissues were homogenized in cold lysis solution containing 150 mmol/L NaCl, 20 mmol/L Tris-HCl (pH 7.6), 1 mmol/L EDTA, 0.5% sodium deoxycholate, 70 mmol/L NaF, 1% Nonidet P-40, complete protease inhibitor cocktail (Boehringer Mannheim), 200 mmol/L sodium orthovanadate, and 2 mmol/L phenylmethylsulfonyl fluoride. After 10 minutes of incubation on ice with intermittent brief vortexing, debris was pelleted in the microcentrifuge, and the supernatants were stored at −80°C. Protein concentrations were determined using the bicinchoninic acid protein determination kit (Pierce). SDS-PAGE and transfer to nitrocellulose were performed, and identical gels were stained with Coomassie brilliant blue R250 to confirm equal protein loading. The nitrocellulose membranes were rinsed in Tris-buffered saline (pH 7.4) containing 0.1% Tween 20 and identical gels were stained with Coomassie brilliant blue R250 to confirm equal protein loading. The nitrocellulose membranes were rinsed in Tris-buffered saline (pH 7.4) containing 0.1% Tween 20 (TBS-T), and were blocked in 5% nonfat milk/TBS-T for 1 hour at 22°C on a rocking platform. Membranes were rinsed 4 times in TBS-T and then incubated overnight at 4°C on an orbital shaker with primary antibodies diluted in TBS-T containing 5% BSA (Sigma). Antiactive caspase-3 polyclonal antibody (Upstate), anti-Bax polyclonal antibody (Upstate), and anti–Bcl-2 monoclonal antibody (Santa Cruz Biotechnology) were used at a concentration of 0.1 mg/mL. Excess primary antibodies were washed from the nitrocellulose membranes with three 10-minute washes in TBS-T, and then, these membranes were incubated with the appropriate horseradish peroxidase-conjugated anti-rabbit or anti-rabbit secondary antibodies (Amersham) diluted 1:200 in 5% milk/TBS-T for 1 hour at 22°C on a rocking platform. Membranes were rinsed 4 times in TBS-T and then incubated overnight at 4°C on an orbital shaker with primary antibodies diluted in TBS-T containing 5% BSA (Sigma). Antiactive caspase-3 polyclonal antibody (Upstate), anti-Bax polyclonal antibody (Upstate), and anti–Bcl-2 monoclonal antibody (Santa Cruz Biotechnology) were used at a concentration of 0.1 mg/mL. Excess primary antibodies were washed from the nitrocellulose membranes with three 10-minute washes in TBS-T, and then, these membranes were incubated with the appropriate horseradish peroxidase-conjugated anti-rabbit or anti-rabbit secondary antibodies (Amersham) diluted 1:2000 in 5% milk/TBS-T. After 3 further 10-minute washes in TBS-T, bound antibodies were detected with the enhanced chemiluminescence kit (Amersham) and exposed to Kodak X-Omat AR film. Densitometric determination of mean integrated areas under the curve from unsaturated autoradiograms of immunoblots was performed using Scion Image software (National Institutes of Health).

**Microvascular Density**

Microvascular density was determined from paraffin-embedded cross-sections of the heart, which were deparaffinized and stained with anti–CD31 antibody (monoclonal mouse anti-human CD31 endothelial cell, clone JC70A, Dako Corporation, Carpentaria, Calif) using a red-fluorescent secondary antibody (Alexa-594TM fluorophore; Molecular Probes), and then, cover slips were applied with fluorescent mounting medium (Dako Corporation). To confirm this result, microvascular density was also determined on histological sections obtained from hearts perfused with fluorescein-isothiocyanate-conjugated Lycopersicon esculentum lectin (Sigma-Aldrich). Slides were examined using a microscope with a Nikon 20× objective and a 10× eyepiece. The number of microvessels appearing was counted in 5 random fields of vision per region of each tissue section (LV and IVS) using Metamorph software, and the results were expressed as the number of microvessels per 1.27×10⁻² m².

**Fibrosis**

Separate deparaffinized tissue sections were stained with Masson trichrome, which results in fibrotic (collagen-enriched) areas appearing blue, whereas cellular elements appear red. In this way, the ratio between the blue and red areas (fibrosis versus myocardium) serves as an estimate of the progression of the fibrosis. Slides were visualized using a microscope with a Nikon 10× objective and a 10× eyepiece. Blue and red areas were measured in 5 random fields of vision per each part of the tissue section (LV and IVS) using Metamorph software, and the results were expressed as the ratio of the blue to red areas.

**Statistical Analysis**

Data are expressed as the mean±SD. Statistical analyses were performed using the Stat View software package (version 5.0, SAS Institute, Cary, NC). Comparisons between groups were performed using ANOVA with a Dunnett post test for multiple comparisons with the control group (P<0.05). A value of P<0.05 was considered statistically significant.
Institute, Inc, Cary, NC). Differences between the groups were tested for significance by 1-way ANOVA using Bonferroni’s correction for multiple comparisons. After normal distribution was confirmed and equal variance testing was done, the Student t test was used to compare individual data sets. A 2-tailed P value ≤0.05 was considered statistically significant.

**Results**

**Morphology**

The RVs of the PAB group became substantially larger and dilated (Figure 1A). Dilatation started around 4 weeks after PAB so that the RV became 3 times the size of that of the control group at 8 weeks after PAB (Figure 1B). The body weight and the wet weights of the LV of both groups were almost the same (data not shown), but the RV wet weight was almost 3 times that of the control group (P<0.01; Figure 1B). Reflecting RVH, the RV/LV weight ratio in the PAB group increased significantly as the animals grew, whereas those of the control group remained essentially unchanged (P<0.01; Figure 1C). At 8 weeks after PAB, the average RV/LV weight ratio exceeded 1.5.

**Echocardiography**

**Peak Pressure Difference Across PAB and the Tricuspid Valve**

As the animals grew, the estimated peak pressure difference across the PAB site increased, reaching a plateau after 7 weeks (37.9±5.6 mm Hg; Figure 2A). Similarly, the estimated peak pressure difference across the tricuspid valve, which was calculated from the peak flow velocity of tricuspid regurgitation, increased by the 6th week after PAB but remained at almost the same level thereafter (51.7±7.0 mm Hg at 8 weeks; Figure 2B).

**LV Dimensions and LV Function**

Although there was no significant difference in LV free-wall thickness, (Figure 3A), the septum in the PAB group at systole was significantly thinner than that of the control group (P<0.05; Figure 3B). As RV pressure increased, the septum became flat, potentially impairing septal contractility in the PAB group.

LV function was assessed using EF and MPI (Figure 3D and 3E). Although EF seemed to increase in the PAB group (Figure 3E), this was likely to be an overestimation of actual LV systolic function because LV dimensions at end-diastole and end-systole were smaller in the PAB group than in the control group (Figure 3C). For example, at 6 weeks (Figure 3C), LV dimensions at end-systole and end-diastole were 12.6 and 8.8 mm and 10.8 and 7.1 mm in the control group and the PAB group, respectively. The difference between LV dimensions at end-diastole and end-systole was almost the same (3.8 and 3.7 mm) in both groups, but the EF calculated was correspondingly higher in the PAB group than in the control group. On the other hand, the MPI of the PAB group increased slowly after 3 weeks and was significantly higher than that of the control group by 6 weeks after PAB (Figure 3D), indicating reduced LV function in the PAB group.

**Langendorff Perfusion**

The developed pressure-LV balloon volume response seemed to be attenuated in the isolated, Langendorff-perfused LV from PAB animals (Figure 4A). The slope (compliance) of the LV diastolic P-V curve seemed to be somewhat steeper (reduced compliance) in the LV from PAB animals, especially at higher LV volumes (Figure 4B). Impaired LV diastolic function in PAB animals was also suggested by the fact that LV tau was prolonged by 84% (P<0.01) in PAB animals compared with control.

**Apoptosis**

**Cardiomyocyte-Specific TUNEL Staining**

More TUNEL-positive nuclei were found in the PAB group than in the control group (Figure 5A). In each myocardial
portion of the control group, the number of TUNEL-positive nuclei was at a basal level (0.9 to 1.5/1000 nuclei), but the number of TUNEL-positive nuclei increased significantly at 4, 6, and 8 weeks after PAB in both the LV and the septum in the PAB group (Figure 5B).

**Apoptotic Proteins**
The expression of Bax was significantly higher in the PAB group after 6 weeks than in the control group in the septum. As a result, the ratio of Bax to Bcl-2 was significantly higher in the PAB group ($P < 0.01$; Figure 6A). The expression of caspase-3 and -9 in the PAB group was also higher than that of the control group, especially 6 weeks after PAB ($P < 0.01$ at 6 weeks, $P < 0.05$ at 8 weeks; Figure 6B and 6C). These results are consistent with a more proapoptotic milieu in the septum and LV of PAB animals as opposed to control.

**Fibrosis**
Representative areas of fibrosis and myocardium are shown in blue and red, respectively (Figure 7A). The degree of fibrosis is shown as the ratio between blue and red areas in the myocardium (Figure 7B). Although fibrosis progressed gradually as the animals grew in both groups, within 4 weeks, there was significantly more septal fibrosis in the PAB group than in the controls (at 4 weeks, $P < 0.05$; at 6 and 8 weeks, $P < 0.01$; Figure 5B). No difference in overall fibrosis was detected in the LV free wall.

**Microvascular Density**
As the right side of Figure 8B shows, microvessels were well stained by CD31 antibody (red color) and by lectin in Figure 6C (green color). Generally, microvascular density decreased in both groups as the animals matured. By 6 weeks, however, the decrease of microvascular density in the septum and LV of the PAB group was significantly greater than that in the control ($P < 0.05$; Figure 8A). In the septum, the difference was also significant at 8 weeks ($P < 0.05$).

**Discussion**
Recently, HFpEF has been the subject of increased discussion. HFpEF can be indicative of LV diastolic function and is
a potential complication of prolonged hypertension. Although there is extensive literature pertaining to LV hypertrophy and failure caused by chronic pressure overload and other abnormalities, there is little information about LV dysfunction caused by the development of RVH. In this study, we showed not only that RVH influenced LV function, particularly diastolic compliance, after PAB but also that septal and LV cardiomyocyte apoptosis may contribute to the LV dysfunction. Because we performed PAB in 10-day-old rabbits, the development and time course of LV dysfunction in conjunction with the progression of RVH could be demonstrated relatively clearly.

Of course, it is difficult to measure LV function using imaging techniques when the shape of the LV is deformed, as it was here by the progression of RVH. We therefore also used tissue Doppler to determine the MPI (TEI index), which is measured as the sum of isovolumic contraction and relaxation durations divided by ejection time. The tissue Doppler-derived MPI is a simple, semiquantitative, nongeometric index of ventricular function that is applicable to the study of ventricular function in the presence of distorted ventricular morphologies as occurs frequently in CHD. In HFP EF, EF is usually maintained within normal limits, but LV function, particularly diastolic function, is impaired. The results of the Langendorff system and the MPI analyses (where most, if not all, of the MPI abnormality was due to the diastolic duration measurement) indicated that LV relaxation was impaired by RVH; this seemed to be, at least in part, due to reduced compliance of the septum.

In our study, PAB served to cause gradual constriction, leading to RVH, as the animals grew. We therefore consider this a good experimental model because of the gradual onset of the abnormal pressure load and subsequent development and progression of RVH. At 6 weeks after PAB, RV dilatation was almost complete, and the wet weight of the RV of the PAB group was 3 times that of the control group. We found, as a part of this process, that RVH deformed the septum, which flattened and then deviated into the left side of the heart (Figures 1 and 3). Both increased apoptosis and fibrosis seemed to be closely related, at least temporally, to the development of cardiac dysfunction. This dysfunction is on the one hand “macroscopic,” arising from physical com-

Figure 8. Assessment of alterations in microvascular density. A, Graphs portray differences in the numbers of microvessels stained by CD31 antibody. In the septum at 8 weeks and the LV and the RV at 6 and 8 weeks, microvascular density decreased significantly in the PAB hearts. *P < 0.05 versus the control group. B, Representative images of CD31 staining are shown. Microvessels reacting with antibody to the endothelial cell-specific epitope CD31 appear in red (on the right); the merged pseudo-color images stained with DAPI (DNA, nuclei, blue) and desmin (muscle, green) are in panel B on the left. C, Examples of lectin staining of capillaries in isolated-perfused control (top) and PAB (bottom) hearts, visualized as relatively punctuate areas of bright green fluorescence. B and C, Magnification ×200; white scale indicates 100 μm.
pression of the LV as a result of RV enlargement and septal shift. On the basis of our results, we speculate that these local abnormalities of wall stress and deformation contribute to activation of apoptotic pathways (Figures 5 and 6) and potentially to dysregulation of the pro- and antiangiogenic factors that regulate angiogenesis and fibrosis (Figures 7 and 8). The degeneration of cardiomyocytes and inadequate microvascular development contributed to decreased compliance of the LV, further promoting LV dysfunction.

Although normal maturation of the RV was associated with a modest reduction in microvascular density, it seems that RVH markedly decreased the number of small capillaries relative to the amount of myocardial tissue. Whether this is in fact the result of deficient production (angiogenesis) and/or increased destruction, as well as the mechanisms involved, require further study. Interestingly, we have previously found that the process of LV pressure overload hypertrophy is able to effectively inhibit hypoxia-induced proangiogenic signaling; one likely mechanism is an alteration in the balance of endogenous pro- and antiangiogenic regulatory molecules.38 In addition, it will be important to determine whether the apparent “mismatch” of muscle mass to capillary supply is sufficient to impair oxygen and substrate delivery and thereby be a primary cause of cardiomyocyte damage as well as activation of profibrotic pathways, and whether these effects overall are sufficient to result in ventricular failure.39–41

Considering the results of this study, it seems that RV pressure overload in the infant is relatively poorly tolerated and needs to be relieved early, not only to prevent deterioration of RV function but also to prevent pathological remodeling of the IVS and LV as well. This study also shows that pressure overload resulting in RVH causes LV diastolic dysfunction with preservation of EF by exerting both mechanical and molecular effects on the septum and the LV myocardium. In particular, the development of RVH is associated with septal and LV apoptosis, pathological LV remodeling, and reduced LV capillary density. Potential mediators and mechanisms (eg, paracrine versus circulating stimuli) merit further investigation.

Sources of Funding
Supported in part by National Institutes of Health grants HL066186 and HL07434 (to F.X.M.).

Disclosures
None.

References


**CLINICAL PERSPECTIVE**

Heart failure with preserved ejection fraction is closely related to the diastolic left ventricular (LV) dysfunction. Some children with congenital heart disease suffer from heart failure with preserved ejection fraction because right ventricular hypertrophy (RVH) causes the diastolic LV dysfunction. LV dysfunction is the principal physiological disorder leading to heart failure, and progressive LV dysfunction can be a major late complication in patients with chronic RV pressure overload. To investigate this phenomenon, we have created a baby rabbit model that showed progressive RVH. We performed pulmonary artery banding (PAB) in 10-day-old rabbits. PAB gradually constricted the pulmonary artery, resulting in RVH. Our model enabled us to investigate LV function accurately in relation to physical development and to demonstrate clearly how RVH influenced LV function, especially diastolic dysfunction, after PAB in relation to physical development in infant RVH. This study, for the first time, shows that a pressure overload resulting in RVH causes LV diastolic dysfunction with preservation of ejection fraction by exerting both mechanical and molecular effects on the septum and the LV myocardium. In particular, the development of RVH is associated with septal and LV apoptosis, pathological LV remodeling, and reduced LV capillary density. Our overall results indicated that apoptosis occurred immediately soon after PAB, before PAB caused a marked degree of constriction of pulmonary artery, and apoptosis increased during the progress of LV dysfunction. After this, apoptosis progressed as the rabbits grew older until LV dysfunction was almost complete and finally resulted in LV failure due to excessive fibrosis.
Development of Left Ventricular Diastolic Dysfunction With Preservation of Ejection Fraction During Progression of Infant Right Ventricular Hypertrophy
Kazuo Kitahori, Huamei He, Mitsuhiro Kawata, Douglas B. Cowan, Ingeborg Friehs, Pedro J. del Nido and Francis X. McGowan, Jr

_Circ Heart Fail._ 2009;2:599-607; originally published online September 24, 2009; doi: 10.1161/CIRCHEARTFAILURE.109.862664

_Circulation: Heart Failure_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2009 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-3289. Online ISSN: 1941-3297

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circheartfailure.ahajournals.org/content/2/6/599

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation: Heart Failure_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation: Heart Failure_ is online at:
http://circheartfailure.ahajournals.org//subscriptions/